By Cynthia L. Kryder, MS, CCC-Sp Posted: October 2017 Editor Note: The article is part of a newly launched ongoing series about immunooncology (IO) combination therapy, future articles of which […] Read more
Posted: June 2017 By David Planchard, MD, PhD What was the rationale for conducting clinical research in BRAF mutationpositive NSCLC? Recently, progress has been made in characterization of the oncogenic […] Read more
Posted: June 2017 By Cynthia L. Kryder, MS Decades of immunology research have shown that it is possible to harness the power of the immune system to fight cancer. In […] Read more
Posted: February 2017 By Fred R. Hirsch, MD, PhD In the new era of immunotherapy in thoracic cancer, evaluating PD-L1 status remains a clinical challenge. In recognition of the potential […] Read more
Posted: February 2017 By Melody Watson The first plenary session on the last day of IASLC WCLC 2016 covered one of the most exciting areas in NSCLC research today: immunotherapy. […] Read more
By Vassiliki A. Papadimitrakopoulou, MD Lung-MAP (S1400), is a unique master multi-study protocol that incorporates genomic testing of tumors through a next-generation sequencing (NGS) platform (Foundation Medicine) and biomarker-driven therapies […] Read more
By Naiyer A. Rizvi The rapid development of anti-PD-1 and PD-L1 antibodies in cancer underscores the tremendous impact they have had on the cancer landscape and for our patients. The […] Read more
By Tony S. K. Mok, BMSc, MD, FRCPC Patients must first be identified as having an epidermal growth factor receptor (EGFR) mutation before they can benefit from EGFR tyrosine kinase […] Read more
By Erik J. MacLaren, PhD Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), received FDA approval in November 2015 for use in patients with metastatic EGFR […] Read more
By Erik J. MacLaren, PhD Alectinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that was recently approved in the US as a second- line treatment for ALK-rearranged non-small cell […] Read more